The Tirzepatide Revolution: Is Dual Agonism the End of Single-Pathway Therapy?

The Tirzepatide Revolution: Is Dual Agonism the End of Single-Pathway Therapy?   Abstract The development of tirzepatide, a first in class dual glucose dependent insulinotropic polypeptide and glucagon like peptide 1 receptor agonist, represents a potentially transformative advance in the management of type 2 diabetes and obesity. By simultaneously targeting

Dementia Risk Increase In Diabetic Patients With Poor Glycemic Control

Dementia Risk Increase In Diabetic Patients With Poor Glycemic Control Overview This study investigated the association between glycemic variability and dementia risk among 171,964 individuals with type 2 diabetes. Despite optimal glycosylated hemoglobin A1c (HbA1c) levels, variability in HbA1c over the long term was found to increase the hazard of dementia. The

Latest Research Exploring Metformin Connection To Breast Cancer

Latest Research Exploring Metformin Connection To Breast Cancer Overview This study aimed to investigate the relationship between metformin and other antidiabetic medications and the incidence of breast cancer in two large prospective cohort studies. It included 185,181 women from the Nurses' Health Study (NHS; 1994–2016) and NHSII (1995–2017). Information on type 2

Is Type 2 Diabetes Reversible? New Research Challenges Medical Consensus